	US 11,718,676 B2
	Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
Yaima Tundidor Cabado, Havana (CU); Gertrudis Rojas Dorantes, Havana (CU); and Kalet Leon Monzon, Havana (CU)
Assigned to CENTRO DE INMUMOLOGIA MOLECULAR, Havana (CU)
Appl. No. 16/767,356
Filed by CENTRO DE INMUMOLOGIA MOLECULAR, Havana (CU)
PCT Filed Nov. 20, 2018, PCT No. PCT/CU2018/050004 § 371(c)(1), (2) Date May 27, 2020, PCT Pub. No. WO2019/105492, PCT Pub. Date Jun. 6, 2019.
Claims priority of application No. 2017-0148 (CU), filed on Nov. 28, 2017.
Prior Publication US 2021/0002375 A1, Jan. 7, 2021
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2863 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01)]

11 Claims

1. A recombinant monoclonal antibody (mAb) that recognizes the extracellular region of human epidermal growth factor receptor (Her1), wherein the complimentary determining region (CDR)2 of the variable region of the heavy chains of said mAb are selected from the group consisting of SEQ ID NO. 17 and SEQ ID NO. 18, and wherein the CDR1 and CDR3 sequences of the variable region of the heavy chains of said mAb consist of (SEQ ID NO. 9) and (SEQ ID NO.3), respectively, and wherein the CDR sequences of the variable region of the light chains of said mAb consist of CDR 1 (SEQ ID NO. 22), CDR 2 (SEQ ID NO. 23), and CDR 3 (SEQ ID NO. 24).